Biotech Health Medical unknown 

Microdose Psychedelic Insights launches Psychedelic Medicine Series


Microdose Psychedelic Medicine Series


The Psychedelic Medicine Series is dedicated to bringing together practicing clinicians, researchers, and experts to explain and discuss the therapeutic use of psychedelic medicine in practice.


More on YorkPedia:

(YorkPedia Editorial):- Toronto, Ontario Mar 8, 2021 ( – Microdose Psychedelic Insights (“Microdose”), a leader in B2B psychedelic intelligence, is to present a free for health workers, bi-monthly live video discussion series titled “Psychedelic Medicine Series”.

”We don’t know what we don’t know, and with psychedelics entering the mainstream, it is imperative that clinicians are brought up to speed and kept up to date to ensure the most responsible use of these medicines in clinical practice. Medical cannabis is legal in many states, but many doctors won’t recommend CBD/THC because they still aren’t familiar with the medicinal properties. We hope to learn from the cannabis industry and get high-quality information out to the doctors NOW so that by the time the legal framework shifts, clinicians are well informed and ready to be active participants in this emerging frontier of medicine.” – Julia Mirer M.D., event partner.

The first in Psychedelic Medicine Series will feature Dave Phillips Psychotherapist, Dr. Mark Braunstein Founder & CEO, Reconscious Medical, Dr. Pamela Kryskow Ketamine Assisted Therapy, Medical Lead Roots To Thrive, and Hayden Rubensohn, Physician.

Moderated by Lynn Marie Morski President of the Psychedelic Medicine Association, the panelists will cover molecules they work within their practices, biochemistry, legal status/historical use, ongoing clinical research: for which conditions, how, predictions for future research, application in clinical practice: personal experience of practicing clinicians, current procedures/rules, benefits of therapy (and community) during preparation and integration, other beneficial modalities for after the experience.

Details and schedule of the first event are as follows:

Psychedelic Medicine Series starts on Thursday, March 11th, 2021 2 pm EST moderated by Marie Morski President of the Psychedelic Medicine Association


Marie Morski, President, Psychedelic Medicine Association

Dr. Lynn Marie Morski is the president of the Psychedelic Medicine Association, host of the Plant Medicine Podcast, founder of Plant, and the medical director for Way of

Dr. Morski received her medical degree from St. Louis University School of Medicine, did a family medicine residency at Mayo Clinic, and completed a sports medicine fellowship at the University of Arizona. She received her law degree from Thomas Jefferson School of Law and is a member of the California Bar.


Dr. Pamela Kryskow Ketamine Assisted Therapy, Medical Lead Roots To Thrive

Dr. Pamela Kryskow is a medical doctor with a strong interest in chronic pain, mental health, and psychedelic medicine. She is a clinical instructor at UBC and an adjunct professor at VIU. She is one of the founding board members of the Canadian Psychedelic Association. Dr. Kryskow is actively involved in research related to psilocybin, MDMA, ketamine, COVID, mental wellness, and neurogenesis. She is a co-investigator on the largest microdosing study Microdose. which is ongoing with 12000+ enrolled participants. She is the medical lead on the Roots To Thrive Ketamine Assisted Therapy program that treats health care providers and first responders with PTSD, depression, anxiety, and addiction. In real life, she loves hiking in the forest, ocean kayaking, growing kale, and daydreaming in the hammock.

Dr. Mark Braunstein Founder & CEO, Reconscious Medical

Dr. B” is a paradigm-shifting psychiatrist.  Shortly after his residency, he began exploring the use of psychoactive plant-based medicines in the treatment of various psychiatric conditions in both children and adults. Dr. B is the medical director for multiple psychiatric and psychedelic health clinics. He’s a pioneer in wilderness psychiatry and his plant-based dosing protocols have made him a sought-after medical consultant, advisor, and educator. He runs inpatient and outpatient treatment programs focused on addiction treatment. Driven by a passion to educate and elevate humanity to a healthier and happier place, Dr. B is involved in multiple projects focused on expanding access, awareness, research, and safety in the field of psychedelics. With over 25 years of clinical practice, his passion is on blending plant medicine with conventional psychiatry now through technology and telemedicine at his company Reconscious Medical.

Dr. Hayden Rubensohn, Physician

Dr. Hayden Rubensohn completed medical training at the University of Calgary in 2012. He began his residency training in Psychiatry at the University of British Columbia but transferred to the Internal Medicine program in 2014. He completed 4 years of Internal Medicine training, followed by 2 years of subspecialty training in Palliative Medicine.

Dr. Rubensohn is a research therapist with the Multidisciplinary Association for Psychedelic Studies (MAPS) since 2014 and has been involved in Phase 2 and 3 clinical trials using MDMA-Assisted Psychotherapy for PTSD in Vancouver.

Dr. Rubensohn’s hope is to ultimately study psychedelic-assisted psychotherapy in palliative populations to address existential distress and psychospiritual suffering.


March 11th, 2021 at 2 p.m. – 2:45 p.m. Eastern


Registration site:


In each webinar, 3 to 4 featured practicing clinicians will give their expert perspective on the psychedelic molecules they work with within a 10 – 15 minute review. The participants will engage in deep and intimate conversations followed by a Q&A period with the audience.

About Microdose Psychedelic Insights

Microdose Psychedelic Insights aims to unlock the potential of psychedelics through Industry events, market intelligence, original, evidence-based content, strategy, and community. We enable and empower society at large to make better, more mindful decisions about psychedelics and their intersection with healthcare, medicine, and personal growth. We work with the industry’s most influential stakeholders, some of the world’s best-known brands, and an unrivaled network of scientists, researchers, analysts, innovators, investors, and advisors.

Learn more at

Microdose Psychedelic Medicine Series

Media Contact

Microdose Psychedelic Insights



Microdose Psychedelic Insights


Related posts